 |
|
|
| |
EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain |
| |
| |
- Telaprevir French Cohort Authorization for Temporary Use in Genotype 1 Hepatitis C Cirrhotic Patients with Prior Partial Response or Relapse - (12/13/12)
- Results of ENABLE-2, a Phase 3, Placebo-controlled, Multicenter Study of Eltrombopag, Peginterferon Alfa-2b, and Ribavirin Treatment in Patients with Hepatitis C and Thrombocytopenia - (05/23/12)
- Summary from EASL 2012 for Hepatitis C
Will there be an interferon-free HCV therapy for all: upcoming reality or just a vision? written by Jurgen K. Rockstroh M.D., Professor of Medicine
University of Bonn, Germany - (05/22/12)
- Response-guided peginterferon alfa-2a therapy based on HBsAg levels at week 12 and week 24 or 48 improves response rates in HBeAg-negative, genotype D patients - (05/10/12)
- Improved predictive value for sustained immune control in peginterferon (PEGASYS)-treated HBeAg-positive patients using combined HBsAg and HBV DNA levels at week 24 - (05/10/12)
- HCV Reinfection - (05/09/12)
- Relationship between Precore / Core Promoter Mutants, HBeAg levels and Serological Response in HBeAg-Positive Chronic Hepatitis B Patients treated with Nucleos(t)ide Analogues 2 - (05/08/12)
- Relationship between precore / core promoter mutants, HBeAg levels and serological response in HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues - (05/07/12)
- Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B - (05/07/12)
- OUTCOMES OF ENTECAVIR (ETV) AND TENOFOVIR (TDF) COMBINATION THERAPY IN CHRONIC HEP-B PATIENTS WITH PREVIOUS TREATMENT FAILURE - (05/04/12)
- Safety and Efficacy of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B - (05/04/12)
- Tenofovir monotherapy for naïve patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months - (05/04/12)
- Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B : a 4-year field practice, multicenter study - (05/04/12)
- Cost Effectiveness of HCV Treatment in Genotype 1 Naïve Patients in 2012 in France - (05/04/12)
- Use of Telaprevir Plus Peg Interferon/Ribavirin for Null Responders Post OLT With Advanced Fibrosis/Cholestatic Hepatitis C - (05/04/12)
- Ribavirin Dose Modification in Treatment-naïve and Previously Treated Patients Who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies - (05/04/12)
- Early versus delayed treatment of acute hepatitis C: The German HEP - NET Acute HCV - III Study-a randomized controlled trial- - (05/04/12)
- Low rate of on-treatment resistance to danoprevir bosted by ritonavir (DNVr) combined with peginterferon alfa-2a (40KD)/ribavirin: 12 week interim analysis from the DAUPHINE study - (05/04/12)
- GS-6620, A Liver-Targeted Nucleotide Prodrug, Exhibits Antiviral Activity and Favorable Safety Profile Over 5 Days in Treatment Naïve Chronic HCV Genotype 1 Subjects - (05/04/12)
- PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION NS5A INHIBITORS - (05/02/12)
- NOVEL NS5A INHIBITOR ACH-2928 PHASE 1 RESULTS IN HEALTHY VOLUNTEERS AND HCV GT-1 PATIENTS - (05/02/12)
- CHARACTERIZATION OF HCV NS3 PROTEASE VARIANTS FROM PATIENTS ENROLLED IN A 28-DAY PHASE 2A TRIAL OF ACH-1625 DAILY DOSING PLUS PEG-IFN-ALPHA 2A/RBV - (05/02/12)
- CONTINUED HIGH VIROLOGIC RESPONSE RATES WITH ACH-1625 DAILY DOSING PLUS PEGIFN-ALPHA 2A IN A 28-DAY AND 12-WEEK PHASE 2A TRIAL - (05/02/12)
- Triple Therapy With Daclatasvir (DCV; BMS-790052), Peginterferon Alfa-2a and Ribavirin in HCV-Infected Prior Null and Partial Responders: 12-Week Results of Phase 2b COMMAND-2 Trial - (04/27/12)
- ABT-450/ritonavir (ABT-450/r) Combined With Pegylated Interferon Alpha-2a/Ribavirin (P/R) After 3-Day Monotherapy in HCV Genotype 1 (GT1)-Infected Treatment-Naïve Subjects: 12-Week Sustained Virologic Response (SVR12) and Safety Results - (04/27/12)
- ABT-072 or ABT-333 Combined With Pegylated Interferon/Ribavirin After 3-Day Monotherapy in HCV Genotype 1 (GT1)-Infected Treatment-Naïve Subjects: 12-Week Sustained Virologic Response (SVR12) and Safety Results - (04/27/12)
- FINAL RESULTS: Randomized, Double-blind, Placebo-controlled Safety, Anti-viral, Proof of Concept Study of Miravirsen, an Oligonucleotide Targeting miR-122, in Treatment-Naïve Patients with Genotype 1 Chronic HCV Infection - (04/27/12)
- Closing Summary by Jean-Michel Pawlotsky: New HCV Drug Development, Goodbye Interferon?, Triple, QUAD, IFN-Free, Adherence, New HCV Drugs - (04/26/12)
- Closing Summary by Jean-Michel Pawlotsky Part 3: New data on telaprevir & boceprevir, post-transplant telaprevir/boceprevir treatment in patients with severe recurrence - (04/26/12)
- Closing Summary by Jean-Michel Pawlotsky Part 2: New HCV Models - (04/26/12)
- Closing Summary by Jean-Michel Pawlotsky Part 1 Genetics, HBV Clinical Guidelines, HBV, HCV Fibrosis Progression, HBC Nucleotides, Alisporivir for HBV - (04/26/12)
- Resistance: Meeting the Challenge: A- Telaprevir, B- Boceprevir Christophe Sarrazin - (04/26/12)
- CUPIC: French Early Access Program - Compassionate Use of Protease Inhibitors in Viral C Cirrhosis - (04/26/12)
- Asunaprevir (ASV; BMS-650032), an NS3 Protease Inhibitor, in Combination With Peginterferon and Ribavirin in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C Infection - (04/25/12)
- Safety and Antiviral Activity of ABT-267, a Novel NS5A Inhibitor, During 3-Day Monotherapy: First Study in HCV Genotype-1 (GT1)-Infected Treatment-Naïve Subjects - (04/25/12)
- ABT-267 Combined With Pegylated Interferon Alpha-2a/ribavirin in Genotype 1 (GT1) HCV-Infected Treatment-Naïve Subjects: 12-Week Antiviral and Safety Analysis - (04/25/12)
- Antiviral Activity and Resistance Profile of the Novel HCV NS5A Inhibitor GS-5885 - (04/25/12)
- Persistence of NS5A Drug Resistance Mutations Following 3 Days of GS-5885 Monotherapy in Genotype-1 HCV Patients is Dependent on the HCV Subtype and Specific Mutation - (04/25/12)
- A Phase 2a Study of BMS-791325, an NS5B Polymerase Inhibitor, With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection - (04/25/12)
- IDENTIFICATION AND CHARACTERIZATION OF PPI-383, A NEXT GENERATION HCV NS5BNON-NUCLEOSIDE INHIBITOR WITH POTENT ACTIVITY AGAINST ALL MAJORHCV GENOTYPES - (04/25/12)
- Presidio Pharmaceuticals Announces Phase 1a-1b Clinical Results with PPI-668, a Potent Pan-genotypic HCV NS5A Inhibitor - (04/25/12)
- Presidio Pharmaceuticals Announces a New Clinical Candidate, PPI-383, a Novel Pan-Genotypic Non-Nucleoside Polymerase Inhibitor for HCV - (04/25/12)
- The Effect of Renal Impairment and End Stage Renal Disease on the Single-Dose Pharmacokinetics of GS-7977 - (04/25/12)
- GS-7977 400 mg QD Safety and Tolerability in the Over 500 Patients Treated for at Least 12 Weeks - (04/25/12)
- Persistence of NS5A Drug Resistance Mutations Following 3 Days of GS-5885 Monotherapy in Genotype-1 HCV Patients is Dependent on the HCV Subtype and Specific Mutation - (04/25/12)
- Patients of all IL28B Genotypes have High SVR Rates when Treated with VX-222 in Combination with Telaprevir/Peginterferon/Ribavirin in the ZENITH Study - (04/24/12)
- INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS - (04/24/12)
- SVR24 AMONG G1/4 TREATMENT-NAIVE PATIENTS RECEIVING MERICITABINE IN COMBINATION WITH PEG-IFNα-2A/RBV: FINAL ANALYSIS FROM THE JUMP-C STUDY - (04/24/12)
- Interferon-Free Regimens at EASL - (04/24/12)
- Patients of all IL28B Genotypes have High SVR Rates when Treated with VX-222 in Combination with Telaprevir/Peginterferon/Ribavirin in the ZENITH Study - (04/24/12)
- GS-9669, A Novel NS5B Non-Nucleoside Thumb Site II Inhibitor, Demonstrates Potent Antiviral Activity, Favorable Safety Profile and Potential for Once-Daily - (04/24/12)
- The Effect of Hepatic Impairment on the Safety, Pharmacokinetics, and Antiviral Activity of GS-7977 in Hepatitis C Infected Subjects Treated for Seven Days - (04/24/12)
- In Vitro Resistance Analysis of Merck's HCV NS5a Inhibitor MK-8742 Demonstrates Increased Potency AgainstClinical Resistance Variants and Improved Resistance Profile - (04/23/12)
- Gilead, Bristol Hep C Drug Data Arrives at EASL: 100% Cure Rate with Bristol's phase II study of daclatasvir plus Gilead's GS-7977 in patients with genotypes 1, 2, and 3: SVR4 (early cure) rate in the genotype 1 patients: 100%. In genotype 2/3 patients, the SVR4 rate was 91%. - (04/23/12)
- Futility Rules in Telaprevir Combination Treatment - (04/23/12)
- 100% SVR in IL28B SNP rs12979860 C/C patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial - (04/23/12)
- A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN - (04/23/12)
- A 12-Week Interferon-Free Regimen of ABT-450/r + ABT-333 + Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naïve HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders - (04/23/12)
- Pancreatitis Forces Halt to HCV Drug Trial - (04/22/12)
- Sustained Virologic Response (SVR) in Prior PegInterferon/Ribavirin (PR) Treatment Failures After Retreatment with Boceprevir (BOC) + PR: PROVIDE Study Interim Results - (04/22/12)
- SVR4 and SVR12 with an interferon-free regimen of BI 201335 AND BI 207127, +/- ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2 - (04/22/12)
- Alisporivir (ALV) plus Peg-interferon/Ribavirin (PR) in HCV G1 Treatment-experienced Patients Achieves Primary Endpoint with Superior Efficacy at Treatment Week 12 Compared to Retreatment with PR - (04/22/12)
- Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-G2 or G3 patients: SVR12 results from VITAL-1 Phase 2b study - (04/22/12)
- RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNα-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 36 INTERIM ANALYSIS - (04/22/12)
- RITONAVIR SUBSTANTIALLY REDUCES REACTIVE METABOLITE FORMATION OF THE HCV PROTEASE INHIBITOR DANOPREVIR BOTH IN VITRO AND IN VIVO - (04/21/12)
- Once Daily GS-7977 Plus Ribavirin in HCV Genotypes 1-3: The ELECTRON Trial - (04/21/12)
- Gilead: Interim Sustained Virologic Response Rates in Treatment-Naïve HCV Genotype 1a and 1b Patients Treated for 12 or 24 Weeks with an Interferon-Free All-Oral Quad Regimen - (04/21/12)
- The efficacy and safety of the interferon-free combination of BI 201335 and BI 207127 in genotype 1 HCV patients with cirrhosis: Interim analysis from SOUND-C2 - (04/20/12)
- GS-7977 + PEG/RBV in HCV Genotype 1: The ATOMIC Trial An End To Response-Guided Therapy - (04/20/12)
- GS-7977 Phase 2 Trials: Concordance of SVR4 with SVR12 and SVR24 in HCV Genotypes 1-3 - (04/20/12)
- Peginterferon Lambda-1A (Lambda) Compared With Peginterferon Alfa-2A (Alfa) in Treatment- Naive Patients With HCV Genotypes 2 or 3: First SVR24 Results From EMERGE Phase IIb - (04/20/12)
- Dual Oral Therapy with NS5A Inhibitor Daclatasvir (BMS-790052) and NS3 Protease Inhibitor Asunaprevir (BMS-650032) in HCV Genotype 1b-Infected Null Responders or Patients Ineligible/Intolerant to Peginterferon/Ribavirin - (04/19/12)
- TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised Phase IIb trial - (04/19/12)
- TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon / ribavirin treatment: Virologic analyses of the ASPIRE trial - (04/19/12)
- Potent Viral Suppression With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (Nucleotide NS5B Inhibitor), +/- Ribavirin, in Treatment-Naive Patients With Chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2) - (04/19/12)
- A 12-Week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naïve HCV IL28B-CC Genotype-1-Infected Subjects - (04/19/12)
- All-Oral Combination of Investigational Hepatitis C (HCV) Compounds Daclatasvir and GS-7977 Achieved Sustained Virologic Response (SVR4) in 100% of Genotype 1 and 91% of Genotype 2 and 3 Treatment-Naïve Patients in Phase II Study - press release - (04/19/12)
- Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients - press release - (04/19/12)
- Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients - press release - (04/19/12)
- Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients - press release - (04/19/12)
- Viral cure achieved without interferon in up to 82% of hepatitis C patients (GT-1a & -1b*): protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, both with and without ribavirin (Boerhinger Ingelheim) - press release - (04/19/12)
- First ever data investigating interferon-free treatment in hepatitis C patients who have liver cirrhosis shows high viral cure rate: protease inhibitor BI 201335 plus the polymerase inhibitor BI 207127 plus ribavirin (Boerhinger Ingelheim) - (04/19/12)
- Confirmation That Quadruple Therapy With Daclatasvir (NS5A Inhibitor), Asunaprevir (NS3 Inhibitor) and Peginterferon/Ribavirin Results in a High Rate of SVR4 in HCV Genotype 1 Null Responders - (04/19/12)
- Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C - Press Release - (04/19/12)
|
|
| |
|
|
|
|
|
|
